Department of Radiation Therapy and Special Oncology, Medical School Hannover, Hannover, Germany.
University of Duisburg-Essen, Essen, Germany.
Integr Cancer Ther. 2022 Jan-Dec;21:15347354221081770. doi: 10.1177/15347354221081770.
Patients with cancer receiving oncological treatment often suffer from a reduced quality of life (QoL) and resilience.
The aim of this study was to evaluate the effect of an interdisciplinary integrative oncology group-based program on resilience and quality of life in patients with cancer during or after conventional oncological therapy.
This prospective longitudinal single-center study evaluated the resilience (Resilience Scale), quality of life (EORTC-QLQ C30), anxiety, depression (Hospital Anxiety and Depression Scale), and distress levels (Distress Thermometer) of 60 patients with cancer who participated in a 10-week interdisciplinary integrative oncology group-based program during or after cancer treatment in outpatient clinics. An average of 12 (range 11-13) patients participated in each 10-week group. The program included recommendations for diet, stress management, relaxation, and exercise, as well as naturopathic self-help strategies and psychosocial support.
There were slight increases in global quality of life scores (week 0: 58.05 ± 20.05 vs week 10: 63.13 ± 18.51, n = 59, = .063, = -.25) and resilience scores (week 0: 63.50 ± 13.14 vs week 10: 66.15 ± 10.17, n = 52, = .222, = -.17) after the group program compared to before; however, these changes were not statistically significant and had small effect sizes. Patients with at least moderate anxiety symptoms ( = .022, = .42) and low resilience ( = .006, = -.54) benefited most from the program. The patients reported no relevant side effects or adverse events from the program.
No significant effects on global quality of life or resilience were found in the general sample; notably, patients with anxiety and low initial resilience benefited the most from the program.
接受肿瘤治疗的癌症患者通常生活质量(QoL)和韧性降低。
本研究旨在评估基于肿瘤学多学科整合小组的方案对癌症患者在常规肿瘤治疗期间或之后的韧性和生活质量的影响。
这是一项前瞻性纵向单中心研究,评估了 60 名癌症患者的韧性(韧性量表)、生活质量(EORTC-QLQ C30)、焦虑、抑郁(医院焦虑和抑郁量表)和困扰水平(困扰温度计),这些患者参加了 10 周的基于肿瘤学多学科整合小组的方案,该方案在癌症治疗期间或之后在门诊进行。每个 10 周的小组平均有 12 名(范围为 11-13 名)患者参加。该方案包括饮食、压力管理、放松和运动的建议,以及顺势疗法自助策略和社会心理支持。
与治疗前相比,整体生活质量评分(第 0 周:58.05±20.05 vs 第 10 周:63.13±18.51,n=59, =.063, =.25)和韧性评分(第 0 周:63.50±13.14 vs 第 10 周:66.15±10.17,n=52, =.222, =.17)略有增加,但这些变化无统计学意义,且效应量较小。至少有中度焦虑症状( =.022, =.42)和低韧性( =.006, =.54)的患者从该方案中获益最多。患者报告该方案无相关副作用或不良事件。
在一般样本中,该方案对整体生活质量或韧性没有显著影响;值得注意的是,有焦虑和初始韧性低的患者从该方案中获益最多。